PaxMedica, Inc. (PXMD) AI Stock Analysis

• Market Cap: $1.09K
• Dividend Yield: N/A
• Average Volume (3M): 37.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 23.43
• Revenue Growth: N/A
• EPS Growth: 79.21%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -6.88
• Shares Outstanding: 10,879,170
• 10 Day Avg. Volume: 1,549
• 30 Day Avg. Volume: 37,622
• PEG Ratio: 0.00
• Price to Book (P/B): -8.51K
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.99K
• Enterprise Value/Market Cap: 768.42K
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -11.67
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 32 Underperform
• Price Target: ―

PaxMedica's significant financial challenges, including no revenue and negative cash flows, weigh heavily on its stock score. Technical indicators suggest a bearish trend, and valuation metrics are poor with a negative P/E ratio. The lack of guidance or highlights from the earnings call provides limited insight into future prospects, resulting in a low overall score.

PaxMedica, Inc. Business Overview & Revenue Model

Company Description

PaxMedica, Inc. (PXMD) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address unmet needs in the field of neurodevelopmental disorders and other central nervous system conditions. The company's primary focus is on the development and commercialization of novel treatments, with its lead product candidate aimed at treating autism spectrum disorder (ASD) and other related conditions.

How the Company Makes Money

PaxMedica, Inc. generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model is centered around advancing its clinical pipeline through various stages of research and development, with the ultimate goal of obtaining regulatory approval and bringing its therapies to market. Revenue streams may include upfront payments, milestone payments, and royalties from potential partnerships or licensing agreements with larger pharmaceutical companies. Additionally, PaxMedica may seek funding through grants and collaborations to support its research initiatives. However, as a clinical-stage company, it may not yet generate significant revenue from product sales until its therapies reach commercialization.

PaxMedica, Inc. Financial Statement Overview

Summary

PaxMedica, Inc. faces significant financial challenges with no revenue generation, consistent net losses, and negative cash flows. While improvements in equity position and no debt reduce some financial risk, the company needs to focus on revenue generation and operational efficiency.

Income Statement

PaxMedica, Inc. has reported no revenue over the past five years, which is concerning for long-term growth prospects. Consistent net losses over the years reflect challenges in achieving profitability, with the latest net income being significantly negative. The lack of revenue growth and negative profit margins indicate a need for strategic changes.

Balance Sheet

The company has improved its stockholders' equity from a negative position in prior years to a positive balance, which is a positive development. However, the absence of revenue and a low equity ratio suggest limited asset utilization. The company maintains no debt, reducing financial risk, but the overall balance sheet strength is moderate due to low asset levels.

Cash Flow

Operating activities consistently result in negative cash flows, highlighting inefficiencies in core operations. Free cash flow remains negative, indicating the company is not generating cash to cover its expenditures. The reliance on financing activities suggests potential liquidity concerns if external funding becomes unavailable.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00	0.00
	EBIT
-15.44M	-16.14M	-10.60M	-7.20M	-5.57M	-599.00K
	EBITDA
-17.66M	-16.14M	-16.51M	-7.20M	-5.62M	-599.00K
	Net Income Common Stockholders
-17.66M	-18.29M	-14.80M	-13.04M	-8.49M	-599.00K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
324.49K	4.71M	1.90M	444.09K	1.12M	24.95K
	Total Assets
799.61K	5.68M	2.20M	648.87K	1.12M	24.95K
	Total Debt
0.00	0.00	173.54K	0.00	611.64K	0.00
	Net Debt
-324.49K	-4.71M	-1.73M	-444.09K	-511.98K	-24.95K
	Total Liabilities
2.61M	2.30M	2.10M	10.76M	5.75M	123.25K
	Stockholders Equity
-1.81M	3.39M	108.80K	-10.11M	-4.63M	-98.30K
Cash Flow		Free Cash Flow
-9.32M	-10.77M	-6.07M	-5.51M	-2.35M	-419.38K
	Operating Cash Flow
-9.32M	-10.77M	-6.07M	-5.51M	-2.35M	-419.38K
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
6.57M	13.58M	7.53M	4.83M	3.45M	435.00K

PaxMedica, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PXMD, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.07, and below the 200-day MA of 0.20, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 37.81 is Neutral, neither overbought nor oversold. The STOCH value of -5.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PXMD.

PaxMedica, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NBIX	74 Outperform	$12.60B	43.17	12.43%	―	21.73%	-19.24%
MNKD	63 Neutral	$1.16B	38.21	-35.00%	―	32.50%	236.33%
AVXL	62 Neutral	$770.91M	―	-40.13%	―	―	-3.08%
Sector *	54 Neutral	$5.24B	3.26	-44.35%	6.48%	16.78%	-0.10%
BTAI	37 Underperform	$10.48M	―	82.91%	―	64.20%	73.71%
PXMD	32 Underperform	$1.09K	―	-540.31%	―	―	79.21%
SHPH	32 Underperform	$3.77M	―	-346.19%	―	―	-7.18%